Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur
About OASIS 4 OASIS 4 was a 64-week phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with one or more weight-related comorbidities.1 People with diabetes were excluded.1 OASIS 4 included a 64-week treatment period, including a 12-week dose escalation, and a 7-week off-treatment follow-up period. In total, 307 participants were randomized in a 2:1 ratio to once-daily oral semaglutide 25 mg or placebo, alongside lifestyle intervention for 64 weeks.1 For those taking Wegovy® pill, 76% achieved 5% or greater body weight loss (from a baseline body weight of 235 lb.) versus 31% taking placebo (from a baseline body weight of 231 lb.).1
About OASIS 4 OASIS 4 was a 64-week phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with one or more weight-related comorbidities.1 People with diabetes were excluded.1 OASIS 4 included a 64-week treatment period, including a 12-week dose escalation, and a 7-week off-treatment follow-up period. In total, 307 participants were randomized in a 2:1 ratio to once-daily oral semaglutide 25 mg or placebo, alongside lifestyle intervention for 64 weeks.1 For those taking Wegovy® pill, 76% achieved 5% or greater body weight loss (from a baseline body weight of 235 lb.) versus 31% taking placebo (from a baseline body weight of 231 lb.).1
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | Novo Nordisk nach Split | ||
| 2 | Novo Nordisk |
|
|
Thema | ||
|---|---|---|---|
| 1 | Dax Prognose | ±0,00 % | |
| 2 | RHEINMETALL Hauptdiskussion | +3,70 % | |
| 3 | DAX Hauptdiskussion | ±0,00 % | |
| 4 | Hims & Hers Health Registered (A) Hauptdiskussion | -3,77 % | |
| 5 | VONOVIA Hauptdiskussion | -0,28 % | |
| 6 | BYD Hauptdiskussion | -1,66 % | |
| 7 | Mercedes-Benz Group Hauptdiskussion | -0,92 % | |
| 8 | Das neue Dax Prognose Forum | ±0,00 % | |
| 9 | Diginex | -2,31 % | |
| 10 | NVIDIA Hauptdiskussion | +1,14 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | RHEINMETALL Hauptdiskussion | +3,71 % | |
| 2 | Hims & Hers Health Registered (A) Hauptdiskussion | -3,77 % | |
| 3 | VONOVIA Hauptdiskussion | -0,28 % | |
| 4 | BYD Hauptdiskussion | -1,66 % | |
| 5 | Mercedes-Benz Group Hauptdiskussion | -1,94 % | |
| 6 | NVIDIA Hauptdiskussion | +1,14 % | |
| 7 | Diginex | -2,31 % | |
| 8 | IPO CSG | +2,85 % | |
| 9 | NBX | -9,31 % | |
| 10 | IDORSIA AG SF-,05 Hauptdiskussion | -2,40 % | Alle Diskussionen |